Immediate vs. deferred switching from a boosted protease inhibitor (PI/r) based regimen to a dolutegravir (DTG) based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96 weeks results of NEAT 022 study

NEAT022 Study Group

Research output: Contribution to journalA1: Web of Science-article

Fingerprint

Dive into the research topics of 'Immediate vs. deferred switching from a boosted protease inhibitor (PI/r) based regimen to a dolutegravir (DTG) based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96 weeks results of NEAT 022 study'. Together they form a unique fingerprint.

Medicine & Life Sciences